Jun 14 |
Seelos Therapeutics files to sell 924K shares of common stock for holders
|
Jun 4 |
FDA advisory panel fails to endorse psychedelic MDMA therapy for PTSD (updated)
|
May 17 |
Seelos Therapeutics announces pricing of about $1M registered direct offering & concurrent private placement
|
May 17 |
Seelos Therapeutics Announces Pricing of $1.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
|
May 14 |
Seelos Therapeutics Announces 1-for-8 Reverse Stock Split
|
Mar 19 |
Dow Jumps 200 Points; Core & Main Shares Gain After Q4 Results
|
Mar 19 |
Seelos drops as lead drug fails in ALS trial
|
Mar 19 |
UPDATE 2-Seelos Therapeutics' ALS treatment fails mid-stage study
|
Mar 19 |
Seelos Therapeutics Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis (ALS) Study with SLS-005 (IV Trehalose)
|
Mar 7 |
Mind Medicine sends psychedelic stocks higher after FDA status for LSD formulation
|